Porcilis ColiClos Euroopan unioni - suomi - EMA (European Medicines Agency)

porcilis coliclos

intervet international bv - clostridium perfringens tyyppi c / escherichia coli-bakteerin f4ab / e. coli-f4ac / e. coli f5 / e. coli, f6 / e. coli lt - immunologian osalta - siat - sillä passiivinen immunisointi jälkeläisten aktiivinen immunisointi emakoille ja ensikoille, vähentää kuolleisuutta ja kliinisiä oireita ensimmäisinä päivinä elämän, niiden aiheuttamaa escherichia coli-kantoja, jotka adhesiineja f4ab (k88ab), f4ac (k88ac), f5 (k99) tai f6 (987p) ja aiheuttanut clostridium perfringens tyyppi c.

Porcilis Porcoli Diluvac Forte (previously Porcilis Porcoli) Euroopan unioni - suomi - EMA (European Medicines Agency)

porcilis porcoli diluvac forte (previously porcilis porcoli)

intervet international bv - f4ab (k88ab) fimbrial adhesiini, f4ac (k88ac) fimbrial adhesiini, f5 (k99) fimbrial adhesiini, f6 (987p) fimbrial adhesiini, lt toksoidi - immunologian osalta - siat (kyyhkyset ja emakot) - porsaiden passiivinen immunisointi emakoiden / nilkkureiden aktiivisen immunisoinnin avulla kuolleisuuden ja kliinisten oireiden, kuten uusiutumiskyvyn aiheuttamaan enterotoksikoosiin liittyvien ripulien, vähentämiseksi, ensimmäisten päivien aikana.. coli-kannoista, jotka ekspressoivat fimbrial adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) tai f6 (987p).

Enteroporc Coli AC Euroopan unioni - suomi - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - siat - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Enteroporc Coli Euroopan unioni - suomi - EMA (European Medicines Agency)

enteroporc coli

ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - immunologiset suidaeille - siat - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.

Spikevax (previously COVID-19 Vaccine Moderna) Euroopan unioni - suomi - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus Euroopan unioni - suomi - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - rokotteet - active immunisation against h5 subtype of influenza a virus.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Euroopan unioni - suomi - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenssa virus pinta-antigeenejä (haemagglutinin ja neuraminidaasin) kanta a, vietnam, 1194, 2004 (h5n1) - influenza, human; immunization; disease outbreaks - rokotteet - aktiivinen immunisaatio influenssa a -viruksen h5n1-alatyypin suhteen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Euroopan unioni - suomi - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - rokotteet - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Jcovden (previously COVID-19 Vaccine Janssen) Euroopan unioni - suomi - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - rokotteet - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Neocolipor Euroopan unioni - suomi - EMA (European Medicines Agency)

neocolipor

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - porsaiden vastasyntyneen enterotoksikoosin väheneminen e: n aiheuttamana. coli-kannoista, jotka ekspressoivat adhesiineja f4ab, f4ac, f4ad, f5, f6 ja f41 ensimmäisten elämänpäivien aikana.